These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1714969)

  • 21. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of postnecrotic and alcoholic hepatic cirrhosis on development of benign prostatic hyperplasia.
    Cetinkaya M; Cetinkaya H; Ulusoy E; Baz S; Memiş A; Yaşa H; Yanik B; Oztürk B; Uzunalimoğlu O
    Prostate; 1998 Jul; 36(2):80-4. PubMed ID: 9655259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide.
    Rittmaster RS
    J Clin Endocrinol Metab; 1988 Oct; 67(4):651-5. PubMed ID: 3138274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
    Lin VC; Liao CH; Wang CC; Kuo HC
    J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Endocrine environment of benign prostatic hyperplasia--relationships of sex steroid hormone levels with age and the size of the prostate].
    Suzuki K; Inaba S; Takeuchi H; Takezawa Y; Fukabori Y; Suzuki T; Imai K; Yamanaka H; Honma S
    Nihon Hinyokika Gakkai Zasshi; 1992 May; 83(5):664-71. PubMed ID: 1379658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine and clinical effects of leuprolide in prostatic cancer.
    Vance MA; Smith JA
    Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of benign prostatic hypertrophy.
    Geller J
    Urology; 1989 Oct; 34(4 Suppl):57-63; discussion 87-96. PubMed ID: 2477935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
    Reis LO; Denardi F; Faria EF; Silva ED
    Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of hormone application by subcutaneous injections or steroid-containing silastic implants on human benign hyperplastic prostate tissue transplanted into male nude mice.
    Claus S; Aumüller G; Tunn S; Senge T; Schulze H
    Prostate; 1993; 22(3):199-215. PubMed ID: 7683815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial.
    Idan A; Griffiths KA; Harwood DT; Seibel MJ; Turner L; Conway AJ; Handelsman DJ
    Ann Intern Med; 2010 Nov; 153(10):621-32. PubMed ID: 21079217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Importance of specific prostatic antigen to prostatic volume ratio in the selection of patients for ultrasonography-guided biopsy of the prostate].
    Veneziano S; Pavlica P; Querzè R; Viglietta G; Trenta A
    Radiol Med; 1991 Jun; 81(6):857-60. PubMed ID: 1713333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
    Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The therapeutic effects of docosahexaenoic acid on oestrogen/androgen-induced benign prostatic hyperplasia in rats.
    Wang C; Luo F; Zhou Y; Du X; Shi J; Zhao X; Xu Y; Zhu Y; Hong W; Zhang J
    Exp Cell Res; 2016 Jul; 345(2):125-33. PubMed ID: 25849092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Oefelein MG; Cornum R
    J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM; Chertin B; Lindenberg T; Farkas A
    N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.